Literature DB >> 9890379

Efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting in patients following infratentorial surgery: a placebo-controlled prospective double-blind study.

P K Sinha1, M Tripathi, S P Ambesh.   

Abstract

In a prospective double blind placebo-controlled study, 45 patients scheduled for infratentorial surgery were randomly allocated into two groups. Five patients were later excluded from the study because of various reasons. Out of 40 analyzable patients, 20 received IV Ondansetron (4 mg), whereas the other 20 received the matching placebo approximately 1 hour before the skin closure. After conclusion of surgery and tracheal extubation, all patients were monitored in the recovery room for post operative nausea and vomiting (PONV) for 48 hours. The incidence of PONV within the first 24 hours was found to be 50% and 10% in the placebo and ondansetron groups, respectively (p<0.05). After 24 hours, however, both groups were comparable in relation to the incidence of emesis. Rescue antiemetic (RAE) was required in nine (45%) patients in the placebo group and in two (10%) patients in the Ondansetron group (p<0.05). A significantly higher number of patients remained sedated postoperatively in the Ondansetron group than in the placebo group (p<0.05). One patient in the Ondansetron group had protracted diarrhea for 48 hours postoperatively. These results indicate that administration of IV Ondansetron (4 mg) 1 hour before skin closure effectively reduces PONV after infratentorial surgery, and does not have significant adverse effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9890379     DOI: 10.1097/00008506-199901000-00002

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  6 in total

1.  Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.

Authors:  Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke
Journal:  Cochrane Database Syst Rev       Date:  2020-10-19

Review 2.  Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis.

Authors:  Andrea C Tricco; Charlene Soobiah; Erik Blondal; Areti A Veroniki; Paul A Khan; Afshin Vafaei; John Ivory; Lisa Strifler; Huda Ashoor; Heather MacDonald; Emily Reynen; Reid Robson; Joanne Ho; Carmen Ng; Jesmin Antony; Kelly Mrklas; Brian Hutton; Brenda R Hemmelgarn; David Moher; Sharon E Straus
Journal:  BMC Med       Date:  2015-06-18       Impact factor: 8.775

3.  Granisetron versus ondansetron for post-operative nausea and vomiting prophylaxis in elective craniotomies for brain tumors: A randomized controlled double-blind study.

Authors:  Priyanka Gupta; Nikki Sabharwal; Suniti Kale; Mayank Gupta; Anoop R Gogia
Journal:  Anesth Essays Res       Date:  2014 Jan-Apr

4.  Anti-emetic Drugs for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy: An Updated Systematic Review and Network Meta-Analysis.

Authors:  Yijing Chen; Jing Chang
Journal:  Front Med (Lausanne)       Date:  2020-02-25

5.  A prospective, randomized, double-blind, and multicenter trial of prophylactic effects of ramosetronon postoperative nausea and vomiting (PONV) after craniotomy: comparison with ondansetron.

Authors:  Jung-Hee Ryu; Ji-Eun Lee; Young-Jin Lim; Deok-Man Hong; Hee-Pyoung Park; Jong-In Han; Hee-Jung Baik; Hyun-Zu Kim; Kyeong-Tae Min; Sang-Hwan Do
Journal:  BMC Anesthesiol       Date:  2014-08-04       Impact factor: 2.217

Review 6.  Postoperative Nausea and Vomiting After Craniotomy: An Evidence-based Review of General Considerations, Risk Factors, and Management.

Authors:  Alberto A Uribe; Nicoleta Stoicea; Marco Echeverria-Villalobos; Alexandre B Todeschini; Alan Esparza Gutierrez; Antonia R Folea; Sergio D Bergese
Journal:  J Neurosurg Anesthesiol       Date:  2021-07-01       Impact factor: 3.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.